Tenax Therapeutics Inc

NASDAQ:TENX   2:39:55 PM EDT
1.20
+0.04 (+3.45%)
Earnings Announcements

Tenax Therapeutics Says Expects Phase 3 Trial Of PAH To Begin In Q2 Of 2022

Published: 11/16/2021 14:27 GMT
Tenax Therapeutics Inc (TENX) - Tenax Therapeutics Inc Says Giordano Was Previously Appointed President, Chief Executive Officer of the Company .
Tenax Therapeutics Inc - Expects Phase 3 Trial of Pulmonary Arterial Hypertension to Begin in Q2 of 2022.
Further Company Coverage: Tenxo ((reuters.
Briefs@thomsonreuters.
Com;)).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.16

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.09

More details on our Analysts Page.